Avenue Therapeutics, Inc. /
Baergic Bio, Inc.
Avenue Therapeutics adds Baergic Bio to its portfolio
- Terms
- Not stated
- Stage
- Closed
What happened
Avenue Therapeutics, Inc. completed its acquisition of Baergic Bio, Inc. from Fortress Biotech, Inc. on Nov. 8, 2022. The transaction transferred a majority of Baergic Bio’s outstanding shares to Avenue.
Baergic Bio is a clinical-stage pharmaceutical company developing products for central nervous system disorders. Its pipeline includes BAER-101, an oral small molecule.
The source
Everything on this page comes from the source below.
Avenue Therapeutics adds Baergic Bio to its portfolio
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly